Seekatz Anna M, Young Vincent B
J Clin Invest. 2014 Oct;124(10):4182-9. doi: 10.1172/JCI72336. Epub 2014 Jul 18.
Clostridium difficile infection (CDI) is the leading health care-associated illness. Both human and animal models have demonstrated the importance of the gut microbiota's capability of providing colonization resistance against C. difficile. Risk factors for disease development include antibiotic use, which disrupts the gut microbiota, leading to the loss of colonization resistance and subsequent CDI. Identification of the specific microbes capable of restoring this function remains elusive. Future studies directed at how microbial communities influence the metabolic environment may help elucidate the role of the microbiota in disease development. These findings will improve current biotherapeutics for patients with CDI, particularly those with recurrent disease.
艰难梭菌感染（CDI）是主要的医疗保健相关疾病。人类和动物模型均已证明肠道微生物群具有提供针对艰难梭菌的定植抗性的能力的重要性。疾病发展的风险因素包括抗生素的使用，这会破坏肠道微生物群，导致定植抗性丧失及随后的CDI。能够恢复此功能的特定微生物的鉴定仍然难以捉摸。针对微生物群落如何影响代谢环境的未来研究可能有助于阐明微生物群在疾病发展中的作用。这些发现将改善目前针对CDI患者，尤其是复发性疾病患者的生物疗法。
